Related Experiment Video

Updated: Jun 7, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995

Enlonstobart: First Approval

Matt Shirley1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 18, 2024
PubMed

Insights

Enlonstobart, a novel antibody targeting PD-1, has gained conditional approval in China for advanced cervical cancer. This marks a significant milestone for treating patients with recurrent or metastatic PD-L1-positive cervical cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Enlonstobart (Enshuxing®) is a fully humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).
  • CSPC Pharmaceutical Group is developing enlonstobart for advanced cervical cancer and other solid tumors.
  • The drug functions by blocking the PD-1 pathway, a key mechanism in immune evasion by cancer cells.

Purpose of the Study:

  • To summarize the development milestones of enlonstobart leading to its first marketing authorization.
  • To highlight the initial approval for recurrent or metastatic PD-L1-positive cervical cancer in China.
  • To provide an overview of ongoing clinical evaluations for first-line cervical cancer treatment and other solid tumors.

Main Methods:

  • Review of clinical development data and regulatory milestones for enlonstobart.
  • Analysis of the drug's mechanism of action as a PD-1 inhibitor.
  • Summary of ongoing Phase II and Phase III clinical trials.

Main Results:

  • Enlonstobart received conditional marketing authorization in China in June 2024.
  • The approval is for patients with recurrent or metastatic PD-L1-positive cervical cancer post-chemotherapy.
  • Phase III trials are evaluating enlonstobart as a first-line treatment for cervical cancer, and Phase II trials are exploring its use in other solid tumors.

Conclusions:

  • The first approval of enlonstobart represents a significant advancement in the treatment landscape for advanced cervical cancer.
  • Enlonstobart's development pathway highlights the potential of PD-1 inhibitors in oncology.
  • Further clinical studies are ongoing to establish its efficacy and safety in broader patient populations and indications.

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.9K
Evaluation of a Novel Laser-assisted Coronary Anastomotic Connector - the Trinity Clip - in a Porcine Off-pump Bypass Model12:00

Evaluation of a Novel Laser-assisted Coronary Anastomotic Connector - the Trinity Clip - in a Porcine Off-pump Bypass Model

Published on: November 24, 2014

15.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
First Pass Effect01:12

First Pass Effect

Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
5.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Factors Influencing Drug Absorption: Presystemic Elimination01:24

Factors Influencing Drug Absorption: Presystemic Elimination

The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
181
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141